Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results

RAD 101 is Radiopharm’s novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid tumors of different origins.Phase 2b Interim Data Shows 90% MRI ConcordanceThe second interim analysis revealed that 90% of patients dosed with RAD 101 achieved concordance with MRI imaging, meeting the primary endpoint of the trial.The results showed significant and selective tumor uptake in the brain metasta ...